Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

News|Videos|May 15, 2023

Various Definitions of Treatment Resistant Depression

Author(s)Lisa Harding, MD

Don't miss this session at the APA 2023 Annual Meeting in San Francisco!

Lisa Harding, MD, shares a preview of her session, "Treatment Resistant Depression From Multiple Perspectives: Does It Exist?" for the APA 2023 Annual Meeting in San Francisco with Carl D. Marci, MD; Joseph Zabinski, PhD; and Steven P. Levine, MD.

Check out this session on Saturday, May 20 at 1:30-3:00PM PDT in Room 303, Moscone South.

Dr Harding is an board-certified psychiatrist and intervention specialist in Milford, CT.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

psychedelic

Podcast: Exploring Entactogens With Hiroe Imai Hu, DO, and James W. Murrough, MD, PhD

ByJenessa Johnston, PhD,Hiroe Hu, DO,James Murrough, MD, PhD

August 13th 2026

Entactogens as a New Frontier for Mood and Anxiety Disorders: A Conversation With Hiroe Imai Hu, DO, and James W. Murrough, MD, PhD

ByJenessa Johnston, PhD

August 13th 2026

TRD: Matching Patients to the Right Treatment

ByMichael E. Thase, MD

August 11th 2026

exercise

Effective Prescription of Exercise for the Treatment of Depression and Anxiety

ByPrerna Gait, MD

August 4th 2026

What Does Interventional Psychiatry Actually Mean? Reframing Non-Standard Treatments for Depression

What Does Interventional Psychiatry Actually Mean? Reframing Non-Standard Treatments for Depression

ByLara Shirikjian, MD

July 31st 2026

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia

DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial

FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease

Phase 4 Trial of Viloxazine ER Shows Real-World Gains for ADHD With Comorbid Depression, Anxiety

New Ingrezza Data Shows Improved Quality of Life and Daily Functioning in Tardive Dyskinesia